Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Clinical Research Workshop

    Product not yet rated Contains 3 Component(s) Recorded On: 10/20/2017

    AASLD's Clinical Research Workshop presented at The Liver Meeting® 2017.

    With the rising epidemic of NASH and NASH-related end stage liver disease, there is a pressing need to better define the pathogenesis of NASH, identify meaningful biomarkers and effective treatments. This workshop aims to bring together investigators from bench to bedside to identify the best methods of collaboration at the translational level, determine how to define meaningful endpoints, and work in teams across disciplines, institutions and with pharma to address this epidemic.

    Anna Mae Diehl

    Manal F. Abdelmalek

    Manal F. Abdelmalek, MD, MPH is tenured Professor of Medicine in the Division of Gastroenterology and Hepatology and Director of the NAFLD Clinical Research Program at Duke University. She received training in Internal Medicine, Gastroenterology and Hepatology at the Mayo Clinic, Scottsdale AZ and Rochester, MN and obtained a MPH degree with emphasis in epidemiology, public health and clinical investigation at the University of Florida, Gainesville, Florida.  Since first reporting on nonalcoholic fatty liver disease (NAFLD) as a cause of cryptogenic cirrhosis over 20 years ago, her clinical and research area of interest have been in the field of NAFLD, its associated risk factors for disease acquisition and progression and novel approaches to treatment. She has expertise in the design and conduct of clinical trials in NAFLD/ NASH including investigator-initiated, industry sponsored and NIH-funded clinical studies evaluating new therapies and biomarkers for NAFLD.  She collaborates extensively to translate new compounds to first-in-man clinical studies and the translation of clinic-to-bench and bench-to-clinic research to define pathogenic mechanisms underlying NAFLD acquisition and progression.  Dr. Abdelmalek is a Fellow of American College of Physicians, American College of Gastroenterology and American Association for the Study of Liver Disease.  She is a standing member of NASH Clinical Research Network (NASH CRN).  She has over 150 publications authored publications in the field of liver disease, the majority of which are in the area of NAFLD. 

    Jag Chhatwal

  • Career Development Workshop

    Product not yet rated Contains 7 Component(s) Recorded On: 10/20/2017

    AASLD's Career Development Workshop presented at The Liver Meeting® 2017.

    If you are considering a career in hepatology, this is the course for you. The Career Development Workshop will educate medical students or residents who are considering a career in hepatology about training opportunities as well as arm current GI and/ or hepatology fellows with knowledge to help them succeed in academic hepatology. Attendees will learn about clinical and basic science research, funding mechanisms, mentorship and important career crossroads. Community based, hybrid practices, and VA-based hepatology opportunities/practice models will be discussed, and an overview of the responsibilities and opportunities of an academic hepatologist and clinician educator will be highlighted. Lastly, through panel discussion, common questions regarding interview and contract negotiations will be reviewed.

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Oren K. Fix

    Oren K. Fix, MD, MSc, FAASLD is Medical Director of the Liver Transplant Program at Swedish Medical Center in Seattle. He earned his medical degree at SUNY Buffalo School of Medicine and a masters degree in Epidemiology from Boston University School of Public Health. He completed his Internal Medicine residency and Gastroenterology fellowship at Boston University and Transplant Hepatology fellowship at University of California San Francisco (UCSF). Dr. Fix was a site principal investigator in the NIH-funded Acute Liver Failure Study Group for 8 years at University of Washington and UCSF. He has published over 45 peer-reviewed manuscripts and book chapters, many on the topic of acute liver failure.

    William Sanchez

    Harmeet Malhi

    Archita P. Desai

    Meena B. Bansal

    Meena B. Bansal, MD, FAASLD is currently Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai, Deputy Chief Medical Officer for Mount Sinai Health Partners, and Vice President, Population Health for Quality and Efficiency. Dr. Bansal attended Harvard University and then Cornell Medical School. She did her internship and residency at Cornell Medical School and then completed Gastroenterology Fellowship at the University of Pennsylvania in 2001.

    Her current research interests focus on the impact of HIV on hepatic inflammation and fibrosis. She became the Director of Translational Research in the Division of Liver Diseases in 2013 and has been principal investigator for numerous clinical trials ranging from HCV to NASH. In 2013, she became the Medical Director of all Hospital-based Clinics at Mount Sinai. In this latter role she developed an interest in population health and the challenges of the evolving health care landscape. Over the past 5 years, her focus has also been on building a population health infrastructure that will allow a large academic health system to be successful in value-based care.

    Mark W. Russo

  • Hepatitis C SIG: HCV Treatment in Persons Who Inject Drugs

    Product not yet rated Contains 9 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations. This program is targeting HCV SIG clinicians, public and global health experts as well as patient advocates with the goal of sharing expertise on how to improve the cascade of care in the “difficult to reach” populations.  

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Camilla S. Graham

    John W. Ward

    Alain H. Litwin

    Christian B. Ramers

    Diana Sylvestre

    Natasha Martin

    Lynn E. Taylor

  • Liver Cell Biology in Hepatic Diseases SIG: DAMPs and New Receptor Signaling in Liver Disease

    Product not yet rated Contains 4 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Gain a solid background on the mechanisms that activate and potentiate hepatic injury, inflammation and fibrosis through an in-depth presentation of the different yet related basic molecular mechanisms that underlie various types of hepatic damage.

    Melanie J. Scott

    Xiaoxia Li

    Nissiam Hay

    Yingzi Yang

  • Hepatotoxicity SIG: Drig-Induced Liver Injury Due to Chemotherapeutic Agents

    Contains 6 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    A look at both traditional and new chemotherapeutic agents associated with liver injury will help attendees gain a working knowledge of agents that can cause liver injury, how the injury presents, and how to make the diagnosis. This program also offers new insight on the challenges for chemotherapeutic drug development, approval and post-marketing surveillance in the U.S.

    Jay H. Hoofnagle

    Robert J. Fontana

    K. Rajender Reddy

    Laurie D. DeLeve

    Arie Regev

    Lorraine Pelosof

  • Hepatitis B SIG: Getting to HBV Cure: The Path Forward

    Contains 12 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    There is a critical need for curative therapy for hepatitis b (HBV). This program will systematically review the various approaches to achieving this goal. Attendees will gain a greater appreciation for the challenges in developing new HBV therapies and discover where new therapies will fit into the future treatment landscape for this disease.

    Jordan J. Feld

    Su H. Wang

    Robert G. Gish

    Dr. Robert G. Gish is a Clinical Professor of Medicine at the University of Nevada in Las Vegas and is a senior consultant at St Joseph’s Medical Center in Phoenix as well as Professor Consultant, Stanford University. In 2013, he founded the consulting company Robert G. Gish Consultants, LLC to provide consultative support to Pharma, nonprofits and hepatology centers and liver transplant programs that wish to start or grow their programs through pathways of quality and optimal patient care that is integrated with research and education. Dr. Gish began his medical training in 1974 when he was enrolled in the pharmacy school at the University of Kansas and then transferred to the University of Kansas Medical School in 1977 and finished his Doctor of Medicine degree in 1980. Dr. Gish went on to complete a three year internal medicine residency at the University of California, San Diego and a four-year gastroenterology and hepatology fellowship at the University of California, Los Angeles. Dr. Gish has had and continues to have an active research program in viral hepatitis, liver transplant, bio-artificial liver, and public policy especially related to liver cancer, liver transplantation, and viral hepatitis.

    Jorg Petersen

    Stephen Locarnini

    Adam J. Gehring

    Scott D. Holmberg

    Mindie H. Nguyen

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

    Norah A. Terrault

    Dr. Norah Terrault is the Professor of Medicine and the Director of the Viral Hepatitis Center at the University of California San Francisco. She is recognized nationally and internationally for her work related to viral hepatitis, especially in the setting of liver transplantation.  She has authored more than 290 original articles, reviews and book chapters on viral hepatitis, including the recent AASLD Hepatitis B Treatment Guidelines. She has served as associate editor for Hepatology, is current Associate Editor for Hepatology Communications and a member of the AASLD HCV Guidance Committee. She is an investigator on several NIH-funded clinical studies in hepatitis B and C, as well as NASH and is an investigator on several ongoing clinical trials of novel therapies for patients with chronic liver diseases.

     

     

    Ju-Tao Guo

    Barbara Rehermann

  • NAFLD SIG: Non-Invasive Diagnosis of NASH: We're getting There

    Product not yet rated Contains 6 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Review the rapidly evolving landscape of non-invasive diagnostic tools for the diagnosis and staging of NAFLD. Non-invasive Diagnosis of NASH will look at the current role of — and available alternatives to —liver biopsy in the assessment of NASH and discuss the controversial issue of utilizing liver biopsy as the “gold-standard” endpoint in clinical trials. The program will review the application of biomarkers in assessing dynamic changes in NAFLD as it pertains to response to therapies and the potential that such biomarkers (serum or imaging) could predict clinical outcomes in NAFLD.

    Zachary D. Goodman

    Anna Mae Diehl

    Quentin M. Anstee

    Stephen A. Harrison

    Christopher Leptak

    Mary E. McCarthy Rinella

  • Alcoholic Liver Disease SIG: Alcoholic Hepatitis: New Therapeutic Strategies Beyond Prednisolone

    Contains 5 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    Alcoholic Hepatitis is the most severe form of Alcoholic Liver Disease (ALD). Currently the most effective form of treatment is Prednisolone, to which many patients do not respond. In the last years, there has been great interest in the development of new targeted therapies for alcoholic hepatitis. In the U.S., there are 4 NIAAA-funded consortia to develop such therapies. In this symposium, we seek to address this issue through the review of current pharmacological therapies, ongoing NIAAA-funded studies, and evaluation of the management of alcohol use disorders in advanced ALD patients. 

    Gene Y. Im

    Vijay Shah

    Shiv K. Sarin

    Craig J. McClain

    Ramon Bataller

  • Pediatric Liver Disease SIG: Drug Induced Liver Injury in Children: Causes, Criteria, and Complications

    Product not yet rated Contains 2 Component(s) Recorded On: 10/20/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    As the number and type of drugs used to treat pediatric illnesses proliferate, and the push to make new drugs available for children gains speed, understanding how to recognize drug-induced liver injury is increasingly important for pediatric liver providers. This program will focus on challenges and opportunities associated with the diagnosis and management of DILI that are unique to the pediatric population. Clinical presentations include surreptitious elevation of serum aminotransferase levels, acute liver injury with or without acute liver failure, and chronic liver disease.

    Binita M. Kamath

    Maclovio J. Lopez

  • Chronic Hepatitis B and Pregnancy: Management and Prevention of Vertical Transmission

    Contains 1 Component(s) Recorded On: 09/14/2017

    Webinar hosted by the Hepatitis B Special Interest group on September 14, 2017.

    The management of women of child-bearing age and pregnant women with chronic hepatitis B requires special consideration due to the potential effects of antiviral therapy on unborn fetus and potential for hepatitis flares for pregnant and postpartum women. While universal maternal screening programs and immunoprophylaxis to newborns have greatly reduced mother-to-child-transmission (MTCT), immunoprophylaxis can fail in up to 30% of infants, especially in mothers with high HBV DNA levels and positive HBeAg. As a result, there has been growing support for the initiation of antiviral therapy during late pregnancy in highly viremic women, and this has been shown in a recent randomized controlled trial to be safe and effective in preventing MTCT with antiviral therapy starting at 30-week gestation and in combination with birth-dose HBV immunoglobulin (HBIG) and vaccination followed by completion of the 3-dose vaccine series.  

    Mindie H. Nguyen (Moderator)

    Mindie H. Nguyen, MD, MAS, AGAF, FAASLD is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology, School of Medicine, Stanford University in Palo Alto, California, USA. Her main fields of scientific and clinical interest are the epidemiology and management of chronic viral hepatitis, non-alcoholic fatty liver disease and liver cancer, with over 100 peer- reviewed scientific journal articles. She has served as a member of the Steering Committee for the Hepatobiliary Neoplasia Special Interest Group, HBV Special Interest Group, Education Committee and the Hepatology Associate Committee for the AASLD and as research mentor for over 100 trainees and faculty.

    Tram T. Tran

    Dr. Tran is Medical Director of Liver Transplantation at Cedars-Sinai Medical Center and Professor of Medicine at Geffen UCLA School of Medicine. Dr. Tran has broad research interests in the areas of viral hepatitis B and C, liver disease in pregnancy and liver transplantation. She is an internationally recognized expert and NIH-funded researcher in the field of chronic hepatitis B, and is active in patient and community advocacy on hepatitis B prevention and treatment. She has authored and co-authored numerous abstracts, papers and chapters in these fields and published in journals.

    Calvin Q. Pan

    Calvin Pan, MD is Clinical Professor of Medicine at the Division of Gasteroenterology and Hepatology in NYU Langone Medical Center in New York. Dr. Pan currently chairs the Online Learning Committee of AASLD. His research interest is a focus on the natural history of viral hepatitis, antiviral therapy and the prevention of vertical transmission of hepatitis virus. As the leading author, Dr. Pan has presented original articles in many high impact journals including the New England Journal of Medicine and Hepatology. He is the recipient of the Mastership Award from the American College of Physicians.